Abstracts / The Breast 20 (2011) S12–S55 S51

node biopsy represented a revolution in the world of breast cancer. First,a therapeutic one minimizing the surgical approach towards "breastcancer", and second, a prognostic one as far as the post-therapeuticprognostic information. Efforts must be done in order to expand theseindications. Sentinel node must be identified every time a complete axil-lary clearence is planned. So, is it time to SYSTEMATICALLY plan sentinelnode biopsy before axillary clearence?

PR113

CLINICOPATHOLOGICAL STUDY OF BREAST CANCER IN YOUNG WOMEN

Mitsuhiko Iwamoto, Nayuko Sato, Hiroya Fujioka, Yuko Takahashi, KoseiKimura, Satoru Tanaka, Kazuhisa UchiyamaOsaka Medical College, Osaka, Japan

Introduction: We herein report that we conducted an examination ofbreast cancer in young women, which is also discussed as a risk factor ofrecurrence or rapid progression.Wewill also refer to cases with interestingclinical courses.Subjects and methods: We conducted a clinicopathological study of 66breast cancer patients under the age of 35 that we treated in our depart-ment between 1981 and 2010.Results: Patients' age ranged from 22 to 34 years, with a mean age of30.8 years. For the tumor diameter, the patients were classified into 6 atT0, 18 at T1, 31 at T2, 8 at T3, and 3 at T4. For histological type, they wereclassified into 58 with invasive ductal carcinoma, 3 with intraductalcarcinoma, and 5 with other types of carcinoma. For clinical staging,they were classified into 6 in Stage 0, 16 in Stage I, 32 in Stage II, 8 inStage III, and 4 in Stage IV. The breast conservation rate of the patientsreached only 29.2% (in these 5 years; 100%). The positive rate of lymphnode metastasis was 39.4% (pN1a:14 pN1b:7 pN2:5), and the both ERand PgR positive rates were 68.2%. The two hormone receptors positiverates of the patients in 20 years old level were 7.1 %. The triple negativerate was 19.7%. High level of Ki67 was observed in 42.4% cases. ER,PgRand Her2 positive rates in 20 years old level patients were significantlylower, and the level of Ki67 was significantly higher than those in 30years old level patients. As adjuvant endocrine chemotherapy, Tamox-ifen was administered for cases being treated with LHRH agonists aswell as ER-positive cases, and we also performed chemotherapy withCMF (w'97) or CAF, FEC (‘98w) after surgery for cases that were positivefor lymph node metastasis or T3,4. CRA(chemotherapy-related amen-orrhea) occurred in 41.0% cases who underwent adjuvant chemotherapy.We are engaged in working on oocyte cryopreservation. Breast cancerrecurred in 12 (18.2%) patients, and the first recurrence sites includedbone in 3, liver in 4, lymph node in 2 lung in 1, brain in 1, local site of thecancer in 1. The Relapse-free Survival(RFS) rate was 81.8%, and theOverall Survival(OS) rate was 86.4%. Both RFS and OS rates in 20 yearsold level patients were significantly lower than those in 20 years oldlevel patients.Conclusions: Breast cancer in young women is known to involve manycases with a poor prognosis, and the cases that were treated in ourdepartment also included many advanced cases, thus leading us to believethat combined modality therapy, including appropriate adjuvant therapy,is required. The biology and clinical courses were different between 20years and 30 years old level patients.

PR114

DEVELOPMENT OF PERSONALIZED MANAGEMENT IN METASTATICBREAST CANCER AT RESOURCE POOR AREA: A COMPREHENSIVEDEFINITION DEVELOPED BY RAJASTHAN CANCER CURE HOSPITALLIMITED JODHPUR INDIA

Suresh Chand Sanchetee 1, Shashank Sanchetee 2

1Rajasthan Cancer Cure Hospital Private Limited, Jodhpur, Rajasthan, India2M G Medical College, Jaipur Rajasthan, India

Personalized management is revalutioning Metastatic Breast Cancer carehold promises for individualizing strong, standardized scientifically soundguidelines for resource poor people which is a basic necessity has hadproven significant impact in the survival of these patients.The potential impact of Molecular [HER2, ER, PR.Ki67, BRCA 1&2 PARPinhibitor] pathway & sub-classification of breast cancer based on genomicprofile, behavior of tumor, newer imaging module, Pharmogenomics andthe individuals preferences, values & goals are important factors indetermining total outcome.Staging of advanced breast Cancer- operable local regional invasiveCarcinoma, in operable local regional invasive carcinoma & Metastatic orrecurrent carcinoma, adjuvant endocrine & molecular manipulation,patient- providers communication, emerging market economics. routinescreening for distress, Supporting patient, appropriately intervention atkey time during cancer journey, training on working staff to deal withthese issues, referral pathway, investigators at many centers testingmultiple combinations to attack multiple targets simultaneously andspreading the technology, web base program to each & all means morerapid translation of scientific advanced to clinical application.My abstract presentation will focus on developing consensus and thepotential role of ABC guideline are a first step in this direction but onlya first step, much more remains.

PR115

RESULTS OF NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITHBREAST CANCER

Anton KhorauGrodno State Medical University, Grodno, Belarus

The purpose of our research was the estimation of efficiency of neo-adjuvant chemotherapy in patients with breast cancer, estimation ofpossible toxic effects of chemotherapy, influence of primary systemicpreoperative therapy on the postoperative period at patients. 25 primarybreast cancer patients (T2-4N 0-3M0) age from 27 till 60 years are includedin research. In the beginning of neoadjuvant chemotherapy performedthe standard core-biopsy needle (14 or 16 gauge) of a tumour for verifi-cation of the diagnosis, definition of the hormonal status and level Her-2/neu. According to standards to patients in one day consistently wereintravenously entered (CAF scheme): cyclophosphamide 500 mg/m2,doxorubicin 50 mg/m2, 5-fluorouracil 500 mg/m2. The interval betweencourses was three weeks. The number of courses of chemotherapydepended on efficiency of treatment and made from 2 to 4 courses (onthe average 3). After neoadjuvant chemotherapy to all patients radicaloperation on a breast has been made. Action of chemotherapy ona tumour studied in dynamics (prior to the beginning of courses neo-adjuvant chemotherapy and before operation) on its linear sizes bypalpation, ultrasonic and mammography. The estimation of efficiency oftreatment was spent by criteria RECIST.Results: The general objective answer on neoadjuvant chemotherapy isrevealed at 18 patients (72 %), stabilisation - at 7 patients (28 %), cancerprogressing were not. Thus the general objective answer was observed atÒ2 at 10 patients (83 %), at Ò3 - at 5 patients (62,5 %) and at Ò4 - at 3patients (60 %). At morphological studying of macropreparations fulldisappearance of all tumoral cells after neoadjuvant chemotherapy isregistered at 5 patients (20 %). Full regress of a tumour at Ò2-Ò3 is noted at16 % of patients, at Ò4 - at 4 %. Toxicity of chemotherapy was 1-2 degrees ofsidemedical effects. It is established, that the chemotherapy did not rendernegative influence of the early postoperative period and did not extendtreatment terms. The tendency to reduction of duration of lymphorrhea isnoted. Quality of a life of patients thus did not suffer.Conclusions: Thus, the obtained data testify, that neoadjuvant chemo-therapy can be an effective component of complex therapy of breast cancerpatients, not limiting terms of surgical treatment and duration of thepostoperative period. Possibly, neoadjuvant chemotherapy in such modewill allow to lower number of the distant metastases and local relapsesand by that to improve results of treatment.